Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 4/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.41 |
| ▸ | CDC25B | P30305 | 3/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7638549 | 0.99 | SSTR1 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7151941 | 0.99 | SSTR1 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7151934 | 0.99 | SSTR1 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7152290 | 0.99 | SSTR1 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7153007 | 0.99 | SSTR1 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7156235 | 0.99 | SSTR1 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7156237 | 0.99 | SSTR1 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7152284 | 0.99 | SSTR1 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7638554 | 0.99 | SSTR1 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL26361027 | 0.88 | SSTR1 (0.41) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) | 2024-04-18 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2022-06-09 | — | — | US | disclosed |
| CN-114025771-A | Glycerol-mannose-heptose ADP derivatives for modulating immune response | 上海药苑生物科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | WUXI PHARMATECH HEALTHCARE FUND I L.P. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-11186606-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| US-20200283468-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | LUMINEX INTERNATIONAL (CN) | 2020-09-10 | — | — | US | disclosed |
| CN-111565726-A | Compositions and methods for modulating immune responses by activating alpha protein kinase 1 | 上海药苑生物科技有限公司 | 2020-08-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | SSTR1 4565/4885SSTR2 4724/4885SSTR4 4821/4885 |
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | GALK1, PHKA1, PGK1 | SSTR1 4688/4885SSTR2 4807/4885SSTR4 4829/4885 |
| US-11186606-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | SSTR1 4565/4885SSTR2 4724/4885SSTR4 4821/4885 |
| US-20200283468-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | SSTR1 4565/4885SSTR2 4724/4885SSTR4 4821/4885 |
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | SSTR1 4565/4885SSTR2 4724/4885SSTR4 4821/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | SSTR1 4565/4885SSTR2 4724/4885SSTR4 4821/4885 |
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | SSTR1 4565/4885SSTR2 4724/4885SSTR4 4821/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | SSTR1 4565/4885SSTR2 4724/4885SSTR4 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.